Every day, MIPS researchers dedicate their time to investigating and designing better medicines. Our research is changing lives, not just in Australia but around the world.
Our many successes are the result of our collaborative, multidisciplinary approach to research excellence, our better drugs by design philosophy and our determination to make a difference to the broad community we serve.
Read how our research is benefitting you and people everywhere.
MIPS is a part of an international effort to address important unmet medical needs in developing countries. View the videos of discussions held at the United Nations in April, 2014.
Helping to bring to market a drug that tamed influenza, one of humanity's biggest killers, ranks among Monash pharmaceutical scientists' proudest achievements.
Leading European drug maker Les Laboratoires Servier has signed a major collaborative agreement with us to exploit our expertise in drug discovery and G protein-coupled receptors (GPCRs), the largest drug-target family in the human genome.
We're helping to turn a toxin found in sea anemones into a promising multiple sclerosis treatment.
Our researchers are collaborating with local and international colleagues to identify new treatments for cancer.
New dosing guidelines, which our researchers helped developed, are turning a last line of defence against highly resistant superbugs into a more effective antibiotic.
Our researchers helped develop a nanosized drug delivery system that can target not just the bloodstream but the lymphatic system, where many cancers are spread and more effectively treated.
Acrux, a Monash spin-off, signed one of the biggest licensing deals in Australian biotech history in 2010 for its testosterone replacement therapy.
Our researchers are members of several award-winning international teams, exploring new ways to treat this devastating tropical disease and control the mosquito-borne parasite that causes it.
US Secretary of State Hilary Clinton praised our research into delivering an old drug more effectively and cheaply to save mothers' lives after childbirth.
Work by our Australian Centre of Pharmaceutical Innovation, which brings together the R&D expertise of the Monash Institute of Pharmaceutical Sciences (MIPS) and GlaxoSmithKline, helped convince GSK to invest $60 million in new manufacturing facilities in Melbourne.